Growth & profitability
- Revenue has declined 7.2% per year over the past 5 years.
Financial health
- Total debt has grown faster than revenue (3.0% vs -7.2% per year).
ENVB Financials Enveric Biosciences, Inc.
15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key annual figures
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | — | $12M | — | — | — | — | — |
| 2024 | — | $10M | — | — | — | — | — |
| 2023 | — | $18M | — | — | -$14M | — | — |
| 2022 | — | -$18M | — | — | -$18M | — | — |
| 2021 | — | -$49M | — | — | -$12M | — | — |
| 2020 | — | -$7M | — | — | — | — | $2M |
| 2019 | $40M | -$2M | 20.4% | -5.8% | — | $6M | $43714 |
| 2018 | $43M | -$17M | 20.9% | -16.6% | — | $5M | $113671 |
| 2017 | — | -$9M | — | — | — | $7M | $5M |
| 2016 | — | -$3M | — | — | — | $5M | — |
| 2015 | — | -$814075 | — | — | — | $5M | — |
| 2015 | — | $423296 | — | — | — | — | — |
| 2014 | — | -$33644 | — | — | — | — | — |
| 2014 | — | $414560 | — | — | — | — | — |
| 2013 | — | -$161 | — | — | — | — | — |
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key quarterly figures
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | — | -$2M | — | — | — | — | — |
| Dec '25 | — | -$2M | — | — | — | — | — |
| Sep '25 | — | -$2M | — | — | — | — | — |
| Jun '25 | — | -$3M | — | — | — | — | — |
| Mar '25 | — | -$2M | — | — | — | — | — |
| Dec '24 | — | -$3M | — | — | — | — | — |
| Sep '24 | — | -$2M | — | — | — | — | — |
| Jun '24 | — | -$2M | — | — | — | — | — |
| Mar '24 | — | -$2M | — | — | — | — | — |
| Dec '23 | — | -$3M | — | — | -$2M | — | — |
| Sep '23 | — | -$3M | — | — | -$3M | — | — |
| Jun '23 | — | -$6M | — | — | -$4M | — | — |
| Mar '23 | — | -$5M | — | — | -$5M | — | — |
| Dec '22 | — | -$9M | — | — | -$3M | — | — |
| Sep '22 | — | -$2M | — | — | -$5M | — | — |
| Jun '22 | — | -$3M | — | — | -$5M | — | — |
| Mar '22 | — | -$5M | — | — | -$5M | — | — |
| Dec '21 | — | -$42M | — | — | — | — | — |
| Sep '21 | — | -$3M | — | — | — | — | — |
| Jun '21 | — | -$908289 | — | — | — | — | — |
Valuation over time
How the market has priced ENVB against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
- The price-to-earnings ratio has risen from 1.0× (Feb '25) to 1.2× (Apr '26).
P/E
Frequently asked questions
Is ENVB growing its revenue and profit?
Over the past 5 years, Enveric Biosciences, Inc.'s revenue has declined 7.2% per year. These are computed facts, not advice.
How much debt does ENVB have?
As of FY2025, Enveric Biosciences, Inc. reported — of total debt against — of cash.
What is ENVB's profit margin?
In FY2025, gross margin was —, operating margin —, and net margin —.
What is ENVB's P/E ratio?
As of Jun '26, Enveric Biosciences, Inc. traded at a price-to-earnings ratio of about 1.2× (market cap ÷ latest annual net income). The valuation charts above show how its P/E have moved with the share price. These are computed facts, not advice.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.